Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (August 2026)
36 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, Aug 25, 2026
Slide 1: Annual Shareholders' Meeting
Annual Shareholders' Meeting 1 25 August 2026
Slide 2: Your Board
Your Board Neville Mitchell Lewis Gradon Mark Cross Anna Curzon Sir Michael Daniell Lisa McIntyre Graham McLean Cather Simpson 2
Slide 3: Agenda
Agenda • Chair’s Address • Managing Director and Chief Executive Officer’s Address • Financial Statements • Resolutions • Voting • General Questions 3
Slide 4: Neville Mitchell, Board Chair
Neville Mitchell Board Chair 4
Slide 5: NZ Campus 1 - Building 5
NZ Campus 1 - Building 5 28,000 m2 / 300,000 ft2
Slide 6: NZ Campus 2 - Karaka
NZ Campus 2 - Karaka Future second campus in South Auckland
Slide 7: 7
7
Slide 8: Your Board
Your Board Neville Mitchell Lewis Gradon Mark Cross Anna Curzon Sir Michael Daniell Lisa McIntyre Graham McLean Cather Simpson 8
Slide 9: Anna Curzon
Anna Curzon New director 9 Fisher & Paykel HEALTHCARE
Slide 10: Margie Apa, Future Director
Margie Apa Future Director 10
Slide 11: Neville Mitchell, Board Chair
Neville Mitchell Board Chair 11
Slide 12: Lewis Gradon, Managing Director and CEO
Lewis Gradon Managing Director and CEO 12
Slide 13: FY26 financial highlights
FY26 financial highlights Operating Revenue $2.31B 12% (cc) Hospital Hardware 27% (cc) Gross Margin 63.7% 122bps Net Profit After Tax $468.5M 28% (cc) Constant currency growth rates 13
Slide 14: 10-year trends
10-year trends Revenue Net Profit After Tax FY26 FY26 $2.31B $468.5M 12% 28% $2.5b $600m $500m $2.0b $400m $1.5b $300m $1.0b $200m $0.5b $100m $0.0b $0m 16 17 18 19 20 21 22 23 24 25 26 16 17 18 19 20 21 22 23 24 25 26 Constant currency growth rates 14
Slide 15: Dividends
Dividends Dividend history FY16 - FY26 60c FY26 Final Dividend 33cps 38% 50c 40c CPS (NZ cents) FY26 Total Dividend 52cps 22% 30c 20c 10-year DPS CAGR 12% 10c 0c 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Interim CPS Final CPS Total CPS 15
Slide 16: Global trade and world events
Global trade and world events
Slide 17: FY27 first half outlook
FY27 first half outlook At 31 July exchange rates*, guidance assumptions for the first half of the 2027 financial year include a continuation of the current trading environment and result in: • Operating revenue of approximately $1.24 billion • Net profit after tax of approximately $280 million. Thi
Slide 18: FY27 full year outlook
FY27 full year outlook At 31 July exchange rates*, our full year guidance is for: • Operating revenue in the range of approximately $2.47 billion to $2.57 billion • Net profit after tax in the range of approximately $525 million to $565 million. The first half and full year net profit after tax guid
Slide 19: Building momentum for the future
Building momentum for the future FY2021 FY2026 Change Comment R&D spend averaging 10.6% of People in Research & Development 684 969 42% revenue over five years. Our global patent portfolio now Patents in the United States 381 768 102% numbers more than 4,500. People in Sales, Marketing & A direct sa
Slide 20: Gross margin recovery
Gross margin recovery Our 5-year margin history 65% 60% 55% 50% 45% FY22 FY23 FY24* FY25 FY26 Long-term gross margin target *Underlying gross margin excludes the product recall provision 20
Slide 21: Revenue growth since 2001
Revenue growth since 2001 Revenue in NZ$ millions by financial year Revenue (NZ$m) $2,500 ~24 million patients $2.31 billion revenue $2,000 $1,500 $1,000 $500 $0 2001 2006 2011 2016 2021 2026 21
Slide 22: Neville Mitchell, Board Chair
Neville Mitchell Board Chair 22
Slide 23: Financial statements
Financial statements • Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor’s report or the company’s 2026 annual report. • There will be an opportunity to ask any general questions once all items on the agenda have been considered. 23
Slide 24: Resolutions
Resolutions 1. Election of Anna Curzon 2. Auditor’s Remuneration 3. Directors’ Remuneration 4. Discretionary Long Term Variable Remuneration to Lewis Gradon 5. Issue of Performance Share Rights – North America 6. Issue of Share Options – North America 7. Issue of Employee Share Rights – North Americ
Slide 25: How to vote online
How to vote online Help line Voting box Question box 25
Slide 26: Neville Mitchell, Board Chair
Neville Mitchell Board Chair 26
Slide 27: Resolution 1: Election of Anna Curzon
Resolution 1: Election of Anna Curzon That Anna Curzon, who being eligible, offers herself for election, be elected as a Director of the company. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 27
Slide 28: Resolution 2: Auditor's Remuneration
Resolution 2: Auditor’s Remuneration That the Directors be authorised to fix the fees and expenses of PwC as the company’s auditor. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 28
Slide 29: Resolution 3: Directors' Remuneration
Resolution 3: Directors’ Remuneration That the maximum aggregate annual remuneration payable to non-executive Directors be increased by NZ$350,000 from NZ$1,750,000 to NZ$2,100,000 (plus GST as appropriate). Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline
Slide 30: Resolution 4: Discretionary Long Term Variable Remuneration
Resolution 4: Discretionary Long Term Variable Remuneration That the grant of discretionary long term variable remuneration instruments to Lewis Gradon, Managing Director and Chief Executive Officer, be approved. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets help
Slide 31: Resolution 5: Issue of Performance Share Rights
Resolution 5: Issue of Performance Share Rights That the Fisher & Paykel Healthcare Corporation Limited 2025 Performance Share Rights Plan – North America be approved. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 31
Slide 32: Resolution 6: Issue of Share Options
Resolution 6: Issue of Share Options That the Fisher & Paykel Healthcare Corporation Limited 2025 Share Option Plan – North America be approved. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 32
Slide 33: Resolution 7: Issue of Employee Share Rights
Resolution 7: Issue of Employee Share Rights That the Fisher & Paykel Healthcare Corporation Limited Employee Share Rights Plan – North America be approved. Click “Submit Vote” to lodge your vote. Need help? Call the MUFG Corporate Markets helpline 0800 200 220 33
Slide 34: Neville Mitchell, Board Chair
Neville Mitchell Board Chair 34
Slide 35: Questions
Questions Questions 35
Slide 36: Thank you for attending today's Annual Shareholders' Meeting
Thank you for attending today’s Annual Shareholders' Meeting 36
Fisher & Paykel Healthcare — Shareholder Meeting (August 2026) on 6ix